CCP
GILD icon

Corient Capital Partners’s Gilead Sciences GILD Stock Holding History

Corient Capital Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$1.56M Buy
25,218
+1,705
+7% +$108K 0.12% 156
2022
Q2 		$1.45M Buy
23,513
+4,917
+26% +$304K 0.11% 168
2022
Q1 		$1.11M Sell
18,596
-1,003
-5% -$64.1K 0.07% 230
2021
Q4 		$1.42M Buy
19,599
+465
+2% +$32K 0.09% 190
2021
Q3 		$1.34M Buy
19,134
+129
+0.7% +$9.06K 0.1% 193
2021
Q2 		$1.31M Buy
19,005
+1,761
+10% +$118K 0.1% 189
2021
Q1 		$1.11M Buy
17,244
+5,865
+52% +$378K 0.1% 188
2020
Q4 		$663K Sell
11,379
-4,064
-26% -$245K 0.07% 231
2020
Q3 		$976K Sell
15,443
-4,921
-24% -$341K 0.11% 168
2020
Q2 		$1.57M Buy
20,364
+5,869
+40% +$450K 0.19% 110
2020
Q1 		$1.08M Buy
14,495
+3,132
+28% +$216K 0.17% 117
2019
Q4 		$739K Buy
11,363
+839
+8% +$54.6K 0.09% 222
2019
Q3 		$667K Sell
10,524
-405
-4% -$26.5K 0.09% 218
2019
Q2 		$738K Buy
10,929
+3,683
+51% +$242K 0.11% 187
2019
Q1 		$471K Sell
7,246
-22,726
-76% -$1.51M 0.08% 230
2018
Q4 		$1.88M Sell
29,972
-12,054
-29% -$843K 0.33% 86
2018
Q3 		$3.25M Hold
42,026
– – 0.54% 43
2018
Q2 		$2.98M Buy
42,026
+5,877
+16% +$415K 0.52% 45
2018
Q1 		$2.73M Buy
36,149
+16,708
+86% +$1.33M 0.5% 51
2017
Q4 		$1.39M Sell
19,441
-14,421
-43% -$1.1M 0.24% 103
2017
Q3 		$2.74M Sell
33,862
-10,064
-23% -$770K 0.52% 47
2017
Q2 		$3.11M Sell
43,926
-645
-1% -$42.9K 0.48% 53
2017
Q1 		$3.03M Sell
44,571
-661
-1% -$46.5K 0.47% 47
2016
Q4 		$3.24M Buy
45,232
+15,005
+50% +$1.12M 0.57% 39
2016
Q3 		$2.39M Buy
+30,227
New +$2.46M 0.44% 49

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Corient Capital Partners's GILD Position: Q3 2022 in Review

Corient Capital Partners increased its Gilead Sciences (GILD) stake by 7.3% in Q3 2022, buying an estimated $108K and bringing the position to 25,218 shares worth $1.56M. The position accounts for 0.12% of the portfolio, ranked #156.

Corient Capital Partners first reported a position in GILD in Q3 2016 and has held it in 25 quarters since. The position peaked at $3.25M in Q3 2018. 1,602 funds tracked by Wall St. Rank hold GILD as of Q3 2022.

  • Corient Capital Partners held 25,218 shares of Gilead Sciences worth $1.56M as of Q3 2022.
  • Corient Capital Partners bought 1,705 Gilead Sciences shares in Q3 2022, an estimated $108K.
  • Gilead Sciences made up 0.12% of Corient Capital Partners's portfolio in Q3 2022, its #156 holding.
  • Corient Capital Partners first reported a position in Gilead Sciences in Q3 2016 and has held it in 25 quarters since.
  • Corient Capital Partners's Gilead Sciences position peaked at $3.25M in Q3 2018.
  • 1,602 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2022.

Based on Corient Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.